Albert Hagège
A5056456796- Cardiomyopathy and Myosin Studies
- Cardiovascular Function and Risk Factors
- Cardiac Valve Diseases and Treatments
- Cardiac Structural Anomalies and Repair
- Tissue Engineering and Regenerative Medicine
- Cardiovascular Effects of Exercise
- Congenital heart defects research
- Cardiac pacing and defibrillation studies
- Cardiac Imaging and Diagnostics
- Trypanosoma species research and implications
- Viral Infections and Immunology Research
- Infective Endocarditis Diagnosis and Management
- Heart Failure Treatment and Management
- Mesenchymal stem cell research
- Mechanical Circulatory Support Devices
- Muscle Physiology and Disorders
- Lysosomal Storage Disorders Research
- Congenital Heart Disease Studies
- Transplantation: Methods and Outcomes
- Electrospun Nanofibers in Biomedical Applications
- Cardiac Arrhythmias and Treatments
- Cardiac Ischemia and Reperfusion
- Pluripotent Stem Cells Research
- Connective tissue disorders research
- Extracellular vesicles in disease
Hôpital Européen Georges-Pompidou
2016-2025
Inserm
2014-2024
Université Paris Cité
2014-2024
Sorbonne Paris Cité
2014-2024
Paris Cardiovascular Research Center
2015-2024
Hôpital Européen
2015-2024
Assistance Publique – Hôpitaux de Paris
2015-2024
Massachusetts General Hospital
1988-2024
Favaloro University
2024
Sequoia (United States)
2024
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their dating.The is not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relationship to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
Phase I clinical studies have demonstrated the feasibility of implanting autologous skeletal myoblasts in postinfarction scars. However, they failed to determine whether this procedure was functionally effective and arrhythmogenic.This multicenter, randomized, placebo-controlled, double-blind study included patients with left ventricular (LV) dysfunction (ejection fraction < or = 35%), myocardial infarction, indication for coronary surgery. Each patient received either cells grown from a...
Background— Clinical trials in heart failure have focused on the improvement symptoms or decreases risk of death and other cardiovascular events. Little is known about effect drugs clinical deterioration surviving patients. Methods Results— We compared angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with angiotensin-converting enzyme enalapril (20 8399 patients reduced ejection fraction a double-blind trial. The analyses prespecified measures nonfatal deterioration. In comparison...
Mitral valve prolapse has been diagnosed by two-dimensional echocardiographic criteria with surprising frequency in the general population, even when preselected normal subjects are examined. In most of these individuals, however, appears apical four-chamber view and is absent roughly orthogonal long-axis views. Previous studies vitro models nonplanar rings have shown that systolic mitral annular nonplanarity can potentially produce this discrepancy. However, to prove directly apparent...
Comparative studies suggest that stem cells committed to a cardiac lineage are more effective for improving heart function than those featuring an extra-cardiac phenotype. We have therefore developed population of human embryonic cell (ESC)-derived progenitor cells. Undifferentiated ESCs (I6 line) were amplified and cardiac-committed by exposure bone morphogenetic protein-2 fibroblast growth factor receptor inhibitor. Cells responding these cardio-instructive cues express the transcription...
Fabry disease ( FD ) is an X‐linked genetic disorder caused by the deficient activity of lysosomal α‐galactosidase (α‐Gal). While males are usually severely affected, clinical presentation in female patients may be more variable ranging from asymptomatic to, occasionally, as affected male patients. The aim this study was to evaluate existence skewed X‐chromosome inactivation XCI females with , its concordance between tissues, and contribution phenotype. Fifty‐six were enrolled. Clinical...
Cell therapy holds promise for tissue regeneration, including in individuals with advanced heart failure. However, treatment of disease bone marrow cells and skeletal muscle progenitors has had only marginal positive benefits clinical trials, perhaps because adult stem have limited plasticity. The identification, among human pluripotent cells, early cardiovascular cell required the development first cardiac lineage would shed light on cardiogenesis might pave way degenerative diseases. Here,...
2D : two-dimensional 99mTc-DPD : 99mTechnetium-3,3-diphosphono- 1,2-propanodi-carboxylic acid ACE : angiotensin-converting enzyme AF : atrial fibrillation AL : amyloid light chain AR : aortic regurgitation ARB : angiotensin receptor blocker ATTR : amyloidosis-transthyretin type AV : atrioventricular BiVAD : biventricular assist device BNP : brain natriuretic peptide BPM : Beats per minute CCS : Canadian Cardiovascular Society CFC : cardiofacialcutaneous CHA2DS2-VASc : Congestive Heart...
AimsIncreased left ventricular wall thickness (LVWT) is a common finding in cardiology. It not known how often hereditary transthyretin-related familial amyloid cardiomyopathy (mTTR-FAC) responsible for LVWT. Several therapeutic modalities mTTR-FAC are currently clinical trials; thus, it important to establish the prevalence of TTR mutations (mTTR) and characteristics patients with mTTR-FAC.
Background: An accurate estimation of the risk life-threatening (LT) ventricular tachyarrhythmia (VTA) in patients with LMNA mutations is crucial to select candidates for implantable cardioverter-defibrillator implantation. Methods: We included 839 adult mutations, including 660 from a French nationwide registry development sample, and 179 other countries, referred 5 tertiary centers cardiomyopathies, validation sample. LTVTA was defined as (1) sudden cardiac death or (2) cardioverter...
Fabry disease (FD) is an X‐linked lysosomal storage disorder caused by pathogenic variants in the α‐galactosidase A ( GLA ) gene that leads to reduced or undetectable enzyme activity and progressive accumulation of globotriaosylceramide its deacylated form globotriaosylsphingosine cells throughout body. FD can be multisystemic with neurological, renal, cutaneous cardiac involvement limited heart. Cardiac characterized hypertrophy, fibrosis, arrhythmias, heart failure sudden death. The...
BackgroundOne of the major determinants exercise intolerance and limiting symptoms among patients with obstructive hypertrophic cardiomyopathy (HCM) is an elevated intracardiac pressure resulting from left ventricular outflow tract obstruction. Aficamten oral selective cardiac myosin inhibitor that reduces gradients by mitigating hypercontractility.MethodsIn this phase 3, double-blind trial, we randomly assigned adults symptomatic HCM to receive aficamten (starting dose, 5 mg; maximum 20 mg)...
Long-term safety and efficacy of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) are unknown. MAVA-LTE (NCT03723655) is an ongoing, 5-year, open-label extension study designed to evaluate the long-term effects mavacamten.
Cardiac myosin binding protein C (MyBP-C) is a sarcomeric belonging to the intracellular immunoglobulin superfamily. Its function uncertain, but for decade evidence has existed both structural and regulatory roles. The gene encoding cardiac MyBP-C (MYBPC3) in humans located on chromosome 11p11.2, mutations have been identified this unrelated families with familial hypertrophic cardiomyopathy (FHC). Detailed characterization of MYBPC3 essential studies regulation, analysis role contraction...
Background —Little information is available on phenotype-genotype correlations in familial hypertrophic cardiomyopathy that are related to the cardiac myosin binding protein C ( MYBPC3 ) gene. The aim of this study was perform type analysis. Methods and Results —We studied 76 genetically affected subjects from nine families with seven recently identified mutations (SASint20, SDSint7, SDSint23, branch point int23, Glu542Gln, a deletion exon 25, duplication/deletion 33) Detailed clinical, ECG,...